Our String of Pearls strategy sets out to accelerate the discovery and development of new therapies by complementing and enhancing our internal capabilities through innovative alliances, partnerships and acquisitions. String of Pearls represents a different way of doing business for the company, and it differentiates Bristol-Myers Squibb from others in the industry. Here are our Pearls to date since our strategy was announced in 2007: Adnexus Therapeutics, KAI Pharmaceuticals, Kosan Biosciences, PDL BioPharma, Exelixis, ZymoGenetics, Nissan Chemical Industries, Teijin Pharma, Medarex and Alder.

Read more about the String of Pearls here.